A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Completed · Phase 1

Conditions studied: Type 1 Diabetes Mellitus

In brief

This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by procedures to look at how the body uses or stores fats and sugars. Participants will continue to use meal time insulin throughout the study. Healthy participants will also enroll in the study. They will not receive any study medication.

Key facts

Study ID

NCT01925989

Run by

Eli Lilly and Company

People needed

27

Starts

2013-11-01

Expected to finish

2015-10-01

Last updated by the study team

2019-03-01

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Type 1 Diabetics:
• T1DM for more than 1 year with Hemoglobin A1c (HbA1c) of less than 9.5%
• All Participants:
• Otherwise fit and healthy
• Non smoker

You may not qualify if…

• Type 1 Diabetics:
• Taking medication or supplements other than insulin to control diabetes
• Suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia
• All Participants:
• Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids

Where it is running

• Translational Research Institute for Metabolism and Diabetes — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.